Uterine sarcoma part III-Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review.

Uterine sarcoma is a very aggressive and highly lethal disease. Even after a comprehensive staging surgery or en block cytoreduction surgery followed by multimodality therapy (often chemotherapy and/or radiation therapy), many patients relapse or present with distant metastases, and finally die of diseases. The worst outcome of uterine sarcomas is partly because of their rarity, unknown etiology, and highly divergent genetic aberration. Uterine sarcomas are often classified into four distinct subtypes, including uterine leiomyosarcoma, low-grade uterine endometrial stromal sarcoma, high-grade uterine endometrial stromal sarcoma, and undifferentiated uterine sarcoma. Currently, evidence from tumor biology found that these tumors showed alternation and/or mutation of genomes and the intracellular signal pathway. In addition, some preclinical studies showed promising results for targeting receptor tyrosine kinase signaling, phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway, various kinds of growth factor pathways, Wnt/beta-catenin signaling pathway, transforming growth factor β/bone morphogenetic protein signal pathway, aurora kinase A, MDM2 proto-oncogene, histone deacetylases, sex hormone receptors, certain types of oncoproteins, and/or loss of tumor suppressor genes. The current review is attempted to summarize the recurrent advance of targeted therapy for uterine sarcomas.

• Publication year

  2016

• Venue

  Taiwanese Journal of Obstetrics & Gynecology

• Publication date

  2016-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.tjog.2016.07.001PMID 27751406
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Uterine carcinosarcoma: the TAG systematic review

  2017cited by this paper
• Outcomes of Patients With Surgically and Pathologically Staged IIIA-IVB Pure Endometrioid-type Endometrial Cancer

  2016cited by this paper
• MLN-8237: A dual inhibitor of aurora A and B in soft tissue sarcomas

  2016cited by this paper
• Is it safe to use minimally invasive surgery in the management of endometrial cancer?

  2016cited by this paper
• Uterine sarcoma Part I-Uterine leiomyosarcoma: The Topic Advisory Group systematic review.

  2016cited by this paper
• Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

  2016cited by this paper
• Pulmonary recurrence in patients with endometrial cancer

  2016cited by this paper
• Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

  2016cited by this paper
• Is it safe to preserve the ovary of premenopausal women with supposed early-stage endometrial cancer?

  2016cited by this paper
• Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.

  2016cited by this paper
• Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma

  2016cited by this paper
• Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults: A Review.

  2016cited by this paper
• Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures.

  2016cited by this paper
• Adjuvant radiation therapy in uterine carcinosarcoma: A population-based analysis of patient demographic and clinical characteristics, patterns of care and outcomes.

  2016cited by this paper
• Challenges in the management of recurrent endometrial cancer.

  2016cited by this paper
• Targeted treatments of sarcomas and connective tumors beside gastrointestinal stromal tumor

  2016cited by this paper
• Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.

  2016cited by this paper
• The role of adjuvant therapy in uterine leiomyosarcoma

  2016cited by this paper
• Gene set-based integrative analysis of ovarian clear cell carcinoma.

  2016cited by this paper
• Uterine sarcoma Part II-Uterine endometrial stromal sarcoma: The TAG systematic review.

  2016cited by this paper
• Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.

  2015cited by this paper
• Potential Therapeutic Targets in Uterine Sarcomas

  2015cited by this paper
• A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†.

  2015cited by this paper
• A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.

  2015cited by this paper
• Immunotherapy of Childhood Sarcomas

  2015cited by this paper
• A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas

  2015cited by this paper
• Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.

  2015cited by this paper
• Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.

  2015cited by this paper
• The Risk of Epithelial Ovarian Cancer of Women With Endometriosis May be Varied Greatly if Diagnostic Criteria Are Different

  2015cited by this paper
• Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.

  2015cited by this paper
• Tumour vascular-disrupting agents in soft-tissue sarcoma.

  2015cited by this paper
• Outcomes and endpoints in cancer trials: bridging the divide.

  2015cited by this paper
• GeDDiS: A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas (EudraCT 2009-014907-29).

  2015cited by this paper
• A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor {alpha} (PDGFR{alpha}) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS).

  2015cited by this paper
• Outcomes and endpoints in trials of cancer treatment: the past, present, and future.

  2015cited by this paper
• A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors

  2014cited by this paper
• Comparison of early-stage primary serous fallopian tube carcinomas and equivalent stage serous epithelial ovarian carcinomas.

  2014cited by this paper
• The off-label use of targeted therapies in sarcomas: the OUTC’S program

  2014cited by this paper
• Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

  2014cited by this paper
• Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database.

  2014cited by this paper
• Neoplasms in the trocar site and peritoneal papillary serous cystadenocarcinoma.

  2014cited by this paper
• Endometriosis and the subsequent risk of epithelial ovarian cancer.

  2014cited by this paper
• Hormone therapy for patients with advanced or recurrent endometrial cancer

  2014cited by this paper
• An increased risk of epithelial ovarian cancer in Taiwanese women with a new surgico-pathological diagnosis of endometriosis

  2014cited by this paper
• Phase I study of olaratumab in Japanese patients with advanced solid tumors

  2014cited by this paper
• Emerging therapies for adult soft tissue sarcoma

  2014cited by this paper
• Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice.

  2014cited by this paper
• One step forward, two steps back.

  2014cited by this paper
• MicroRNAs regulate several functions of normal tissues and malignancies.

  2013cited by this paper
• Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.

  2013cited by this paper
• A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group

  2013cited by this paper
• Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide

  2013cited by this paper
• Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.

  2013cited by this paper
• Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

  2013cited by this paper
• Hormone therapy for younger patients with endometrial cancer.

  2012cited by this paper
• A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials

  2012cited by this paper
• Tumor response assessment by modified Choi criteria in localized high‐risk soft tissue sarcoma treated with chemotherapy

  2012cited by this paper
• Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.

  2012cited by this paper
• Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

  2012cited by this paper
• The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial

  2012cited by this paper
• Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

  2011cited by this paper
• Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

  2009cited by this paper
• Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).

  2009cited by this paper
• Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

  2009cited by this paper
• Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

  2009cited by this paper
• Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.

  2009cited by this paper
• Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).

  2008cited by this paper
• Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

  2005cited by this paper
• Altered mRNA expressions of sialyltransferases in ovarian cancers.

  2005cited by this paper
• Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma

  2004cited by this paper
• Enhanced expression of α 2,6-sialyltransferase ST6Gal I in cervical squamous cell carcinoma

  2003cited by this paper
• One Step Forward, Two Steps Back

  2003cited by this paper
• Enhanced expression of alpha 2,6-sialyltransferase ST6Gal I in cervical squamous cell carcinoma.

  2003cited by this paper
• Different enzyme activities of sialyltransferases in gynecological cancer cell lines.

  2002cited by this paper
• Different enzyme activities of sialyltransferases in gynecological cancer cell lines.

  2002cited by this paper
• Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas.

  2002cited by this paper
• Expression of sialyltransferase family members in cervix squamous cell carcinoma correlates with lymph node metastasis.

  2002cited by this paper
• One step forwards, two steps back

  2000cited by this paper
• Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas.

  1998cited by this paper
• Impact on Progression‐Free Survival of Adjuvant Cyclophosphamide, Vincristine, Doxorubicin (Adriamycin), and Dacarbazine (CYVADIC) Chemotherapy for Stage I Uterine Sarcoma: A Prospective Trial

  1995cited by this paper
• A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.

  1985cited by this paper
• High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma.

  1983cited by this paper
• Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide

  1972cited by this paper
• Biologics: Targets and Therapy Dovepress Targeted Therapy for Sarcomas

  year unknowncited by this paper

• E7050 Suppresses the Growth of Multidrug-Resistant Human Uterine Sarcoma by Inhibiting Angiogenesis via Targeting of VEGFR2-Mediated Signaling Pathways

  2023cites this paper
• Epigenetic Features in Uterine Leiomyosarcoma and Endometrial Stromal Sarcomas: An Overview of the Literature

  2022cites this paper
• Blockade of c-Met-Mediated Signaling Pathways by E7050 Suppresses Growth and Promotes Apoptosis in Multidrug-Resistant Human Uterine Sarcoma Cells

  2022cites this paper
• Comparing paclitaxel-platinum with ifosfamide-platinum as the front-line chemotherapy for patients with advanced-stage uterine carcinosarcoma

  2021cites this paper
• The systemic treatment of uterine leiomyosarcomas

  2021cites this paper
• Recent Advances in Endometrial Cancer

  2020cites this paper
• Uterine Sarcomas: Review and Update

  2020cites this paper
• Malignant perivascular epithelioid cell tumor in the female genital tract

  2019cites this paper
• Uterine sarcoma: An unusual but high lethal disease of gynecological malignancies.

  2019cites this paper
• Genetic and Epigenetic Features in Uterine Smooth Muscle Tumors: An Update

  2019cites this paper
• High-grade endometrial stromal sarcoma: a retrospective study of factors influencing prognosis

  2019cites this paper
• Uterine Sarcomas: An Updated Overview

  2018cites this paper
• Endometrial stromal sarcomas and related neoplasms: new developments and diagnostic considerations.

  2017cites this paper
• Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer.

  2017cites this paper
• Outstanding female cancer research paper awards of the 2016 Taiwan Association of Obstetrics and Gynecology and Hsu Chien-Tien Cancer Foundation.

  2017cites this paper
• Outstanding female cancer research paper awards of the 2015 Taiwan Association of Obstetrics and Gynecology and Hsu Chien-Tien Cancer Foundation.

  2016cites this paper